# OnCo record bcr-signalling (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/bcr-signalling/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "bcr-signalling" ;
  schema:name "B-cell receptor / BTK signalling (to NF-κB)"@en ;
  schema:description "The B-cell receptor is the survival switch of B cells. Signals from it pass through BTK to free NF-kappa-B, which keeps the cell alive. B-cell cancers hold it on; BTK inhibitors, proteasome inhibitors and lenalidomide each cut the line at a different point."@en ;
  schema:url <https://onco.cc/pathways/bcr-signalling/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/B-cell_receptor> ;
  schema:citation <https://en.wikipedia.org/wiki/B-cell_receptor>, <https://doi.org/10.1038/nature08638>, <https://doi.org/10.1038/nature09671>, <https://doi.org/10.1056/NEJMoa1200710> ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/waldenstrom/>, <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/primary-cns-lymphoma/> ;
  onco:targets <https://onco.cc/targets/bcl2/> ;
  onco:drugs <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/venetoclax/> ;
  onco:pathways <https://onco.cc/pathways/inflammation-nfkb/>, <https://onco.cc/pathways/apoptosis-bcl2/> ;
  onco:terms <https://onco.cc/terms/lymphoma-bio-lymphgen/> .